	US 11,918,641 B2
	Chimeric influenza vaccines
Chi-Huey Wong, New Taipei (TW); Hsin-Yu Liao, New Taipel (TW); Shih-Chi Wang, New Taipei (TW); Yi-An Ko, Taipei (TW); Kuo-I Lin, Taipei (TW); Che Ma, New Taipei (TW); and Ting-Jen Cheng, New Taipei (TW)
Assigned to ACADEMIA SINICA, Taipei (TW)
Appl. No. 17/998,208
Filed by ACADEMIA SINICA, Taipei (TW)
PCT Filed May 7, 2021, PCT No. PCT/US2021/031406 § 371(c)(1), (2) Date Nov. 8, 2022, PCT Pub. No. WO2021/226533, PCT Pub. Date Nov. 11, 2021.
Claims priority of provisional application 63/022,328, filed on May 8, 2020.
Prior Publication US 2023/0302114 A1, Sep. 28, 2023
Int. Cl. A61K 39/145 (2006.01); A61K 35/76 (2015.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61P 31/16 (2006.01); C07K 14/005 (2006.01); C07K 14/11 (2006.01)

CPC A61K 39/145 (2013.01) [A61P 31/16 (2018.01); C07K 14/005 (2013.01); A61K 2039/575 (2013.01)]

14 Claims

1. A chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA), wherein the chimeric influenza virus HA polypeptide comprises an amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 8, or SEQ ID NO: 12.